Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Related Press Releases
![Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
![Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
![Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
![Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
![Ipsen appoints Keira Driansky as EVP, President of North America Ipsen appoints Keira Driansky as EVP, President of North America](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen appoints Keira Driansky as EVP, President of North America
![Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
![Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
![Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
![Ipsen S.A. publishes its 2023 Consolidated Financial Statements Ipsen S.A. publishes its 2023 Consolidated Financial Statements](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
![Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)